Toronto Dominion Bank Sells 2,972 Shares of AstraZeneca PLC (NASDAQ:AZN)

Toronto Dominion Bank trimmed its stake in AstraZeneca PLC (NASDAQ:AZN) by 16.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,521 shares of the company’s stock after selling 2,972 shares during the period. Toronto Dominion Bank’s holdings in AstraZeneca were worth $1,210,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. GHP Investment Advisors Inc. bought a new stake in shares of AstraZeneca in the 2nd quarter valued at approximately $26,000. Able Wealth Management LLC bought a new stake in shares of AstraZeneca during the 4th quarter worth approximately $27,000. Pathway Financial Advisers LLC bought a new stake in shares of AstraZeneca during the 1st quarter worth approximately $29,000. Pin Oak Investment Advisors Inc. lifted its stake in shares of AstraZeneca by 468.4% during the 4th quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after acquiring an additional 370 shares during the last quarter. Finally, RFP Financial Group LLC lifted its stake in shares of AstraZeneca by 56.3% during the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after acquiring an additional 178 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

AZN has been the subject of a number of research analyst reports. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. TD Cowen raised their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Barclays raised AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Finally, Citigroup raised AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Up 0.4 %

Shares of NASDAQ AZN opened at $77.91 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $81.66 and a two-hundred day simple moving average of $77.18. The firm has a market cap of $241.57 billion, a PE ratio of 38.19, a price-to-earnings-growth ratio of 1.47 and a beta of 0.47. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The business had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business posted $1.08 EPS. Analysts expect that AstraZeneca PLC will post 4.05 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were given a $0.49 dividend. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend was Friday, August 9th. AstraZeneca’s payout ratio is 48.04%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.